Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL931587 | 0.98 | GSK3B (0.56) | GSK3BL3MBTL1PTPN1MAPTGAA | |
| SCHEMBL11728169 | 0.93 | GSK3B (0.58) | GSK3BL3MBTL1PTPN1MAPTGAA | |
| SCHEMBL15018952 | 0.86 | GSK3B (0.58) | GSK3BL3MBTL1PTPN1MAPTGAA | |
| SCHEMBL5055145 | 0.86 | L3MBTL1 (0.65) | GSK3BL3MBTL1MAPTNPC1THRA | |
| SCHEMBL9786122 | 0.84 | GSK3B (0.59) | GSK3BL3MBTL1PTPN1MAPTGAA | |
| SCHEMBL2356907 | 0.83 | TP53 (0.66) | GSK3BL3MBTL1THRATHRBMMP1 | |
| SCHEMBL6640853 | 0.82 | L3MBTL1 (0.60) | L3MBTL1MAPTGAANPC1MMP1 | |
| SCHEMBL5745992 | 0.82 | GSK3B (0.58) | GSK3BL3MBTL1PTPN1MAPTGAA | |
| SCHEMBL5057170 | 0.82 | L3MBTL1 (0.70) | GSK3BL3MBTL1PTPN1MAPTNPC1 | |
| SCHEMBL7861703 | 0.81 | TP53 (0.69) | GSK3BL3MBTL1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114599362-B | Application of phenylquinolinone and flavonoid derivatives in preparation of medicines for treating neuropathic pain | 杭州百诚医药科技股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-118680931-A | Use of phenylquinolinone and flavonoid derivatives for treating neuropathic pain | 杭州百诚医药科技股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20230295134-A1 | USE OF PHENYLQUINOLINONE DERIVATIVE OR FLAVONOID DERIVATIVE FOR TREATING NEUROPATHIC PAIN | HANGZHOU BIO-SINCERITY PHARMA-TECH CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295134-A1 | USE OF PHENYLQUINOLINONE DERIVATIVE OR FLAVONOID DERIVATIVE FOR TREATING NEUROPATHIC PAIN | HANGZHOU BIO-SINCERITY PHARMA-TECH CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295134-A1 | USE OF PHENYLQUINOLINONE DERIVATIVE OR FLAVONOID DERIVATIVE FOR TREATING NEUROPATHIC PAIN | HANGZHOU BIO-SINCERITY PHARMA-TECH CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| CN-115448877-A | Fused ring pyridone derivative and application thereof | 杭州百诚医药科技股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-114599362-A | Use of phenylquinolinone and flavonoid derivatives for treating neuropathic pain | 杭州百诚医药科技股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2021072642-A1 | USE OF PHENYLQUINOLINONES AND FLAVONOID DERIVATIVES FOR TREATING NEUROPATHIC PAIN | 杭州百诚医药科技股份有限公司 | 2021-04-22 | — | — | WO | disclosed |
| EP-2502918-B1 | Pyridazinone Derivatives | CEPHALON INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140296212-A1 | SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20050085502-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J G (US) | 2005-04-21 | — | — | US | disclosed |
| US-20050085501-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J G (US) | 2005-04-21 | — | — | US | disclosed |
| US-20050049277-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY (US) | 2005-03-03 | — | — | US | disclosed |
| US-20050043348-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY (US) | 2005-02-24 | — | — | US | disclosed |
| EP-1268478-A2 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | Ortho McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6489337-B1 | TREATMENT OF ALZHEIMER'S DISEASE, EPILEPSY, EATING DISORDERS, LEARNING AND MEMORY DISORDERS, MIGRAINE, SLEEP/WAKE DISORDERS, ALLERGIC RHINITIS, SCHIZOPHRENIA, MILD COGNITIVE IMPAIRMENT, AND ASTHMA | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020006934-A1 | Phenyl-substituted imidazopyridines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001074815-A2 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001074813-A2 | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| US-4727145-A | LOCAL ANESTHETICS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043348-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | GSK3B 3509/4885L3MBTL1 4526/4885PTPN1 2431/4885 |
| US-20140296212-A1 | SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | GSK3B 2214/4885L3MBTL1 4844/4885PTPN1 2317/4885 |
| US-20050085502-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | GSK3B 3509/4885L3MBTL1 4526/4885PTPN1 2431/4885 |
| US-20050085501-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | GSK3B 3509/4885L3MBTL1 4526/4885PTPN1 2431/4885 |
| US-20050049277-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | GSK3B 3509/4885L3MBTL1 4526/4885PTPN1 2431/4885 |
| US-20230295134-A1 | USE OF PHENYLQUINOLINONE DERIVATIVE OR FLAVONOID DERIVATIVE FOR TREATING NEUROPATHIC PAIN | HRH4, HRH2, HRH1 | GSK3B 1238/4885L3MBTL1 4344/4885PTPN1 4113/4885 |
| US-20020006934-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | GSK3B 3509/4885L3MBTL1 4526/4885PTPN1 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.